Hong Kong Pharmaceutical stocks plunged straight in the afternoon

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.

Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar

Mabwell (Shanghai) Bioscience Co., Ltd.（迈威（上海）生物科技股份有限公司）has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.

Insilico Medicine (英矽智能) Signs Strategic Drug Discovery Partnership with Takeda (武田制药), Deal Worth Up to US$600 Million

Chinese AI drug discovery company Insilico Medicine (英矽智能) has signed a global strategic collaboration with Japanese pharmaceutical company Takeda (武田制药), with the total potential deal value reaching up to US$600 million. Announced in early July, the agreement marks another milestone in the international commercialization of China's AI-powered drug discovery technologies through collaboration with a leading multinational pharmaceutical company.

Drug Farm Raises $55 Million in First Closing of Series D Financing

According to EO (亿欧), Drug Farm (药物牧场) announced on July 13 that it had raised $55 million in the first closing of its Series D financing round.